[Long-term intravesical treatment with adriamycin in chemoprevention of recurrence of transurethrally resected urinary bladder cancers].
64 patients with a histologically verified urothelial tumour of the urinary bladder were given intravesical Adriamycin-instillations after transurethral resection of their tumours. 34 patients received 50 mg Adriamycin once weekly for a period of 6 weeks. 30 patients, after undergoing this initial treatment, were treated with 50 mg Adriamycin once a month over a period of 2 years. After 1 year we found a relapse rate in the group with a long term therapy as compared with the first group a relapse rate of 32%. After 2 years of observation the relapse rate was practically the same in both groups (41% and 40%).
D000283:Administration, Intravesical; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000517:prevention & control* / Q000601:surgery; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control* / Q000601:surgery
D004317:Doxorubicin
Intravesikale Langzeitbehandlung mit Adriamycin als Chemorezidivprophylaxe transurethral resezierter Harnblasenkarzinome.